Literature DB >> 1321419

Catecholamines and vitiligo.

A Morrone1, M Picardo, C de Luca, O Terminali, S Passi, F Ippolito.   

Abstract

The levels of some catecholamine metabolites, namely homovanillic acid (HVA), vanilmandelic acid (VMA), 3-methoxytyramine (MT), normetanephrine (NMN), metanephrine (MN), 3,4-dihydroxy mandelic acid (DOMAC), and 3,4-dihydroxy phenylacetic acid (DOPAC), have been evaluated in the 24 hr urines of 150 patients affected with different types of vitiligo and in 50 healthy age-matched individuals. The patients were divided into three groups according to the different phases of the disease. The first group included subjects affected either with the early active phase or with progressive increase in both number and/or the size of previous lesions. The second group included patients in whom no new lesions had appeared for between 4-8 months. In the third group the white areas had been stable for 1-5 years. The first and second groups showed values of HVA and VMA from 4 to 10 times and from 1/2 to 3 times higher respectively than those of controls, while no significant differences were found between the third group and controls. Our results clearly show that a significant increase of urinary levels of HVA and VMA, deriving respectively from dopamine and from norepinephrine and epinephrine characterizes the onset and the progressive active phases of vitiligo, irrespective of the type of distribution. The increased release of catecholamines from the autonomic nerve endings in the microenvironment of melanocytes in the affected skin areas might be involved in the etiopathogenesis of vitiligo through two main mechanisms: (1) a direct cytotoxic action of catecholamines and/or their o-diphenol catabolites; (2) an indirect action.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1321419     DOI: 10.1111/j.1600-0749.1992.tb00003.x

Source DB:  PubMed          Journal:  Pigment Cell Res        ISSN: 0893-5785


  22 in total

Review 1.  Highlights in pathogenesis of vitiligo.

Authors:  Ghada F Mohammed; Amal Ha Gomaa; Mohammed Saleh Al-Dhubaibi
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

Review 2.  New treatment modalities for vitiligo: focus on topical immunomodulators.

Authors:  Kresimir Kostovic; Aida Pasic
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Increased monoamine oxidase A activity in the epidermis of patients with vitiligo.

Authors:  K U Schallreuter; J M Wood; M R Pittelkow; G Buttner; N Swanson; C Korner; C Ehrke
Journal:  Arch Dermatol Res       Date:  1996       Impact factor: 3.017

4.  Erythrocyte malondialdehyde and glutathione levels in vitiligo patients.

Authors:  Jung Won Shin; Kyung Mi Nam; Hye Ryung Choi; Sun Young Huh; Shin Woo Kim; Sang Woong Youn; Chang Hun Huh; Kyoung Chan Park
Journal:  Ann Dermatol       Date:  2010-08-05       Impact factor: 1.444

5.  The occurrence of cutaneous nerve endings and neuropeptides in vitiligo vulgaris: a case-control study.

Authors:  P Y Liu; L Bondesson; W Löntz; O Johansson
Journal:  Arch Dermatol Res       Date:  1996-10       Impact factor: 3.017

6.  Catechol-O-methyltransferase in vitiligo.

Authors:  I C Le Poole; R M van den Wijngaard; N P Smit; J Oosting; W Westerhof; S Pavel
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

Review 7.  The Role of the NKG2D in Vitiligo.

Authors:  Lourdes Plaza-Rojas; José A Guevara-Patiño
Journal:  Front Immunol       Date:  2021-02-26       Impact factor: 7.561

Review 8.  Stability in Vitiligo: Is there a Perfect Way to Predict it?

Authors:  Kanika Sahni; Davinder Parsad
Journal:  J Cutan Aesthet Surg       Date:  2013-04

9.  Potential redox-sensitive Akt activation by dopamine activates Bad and promotes cell death in melanocytes.

Authors:  Hye-Ryung Choi; Jung-Won Shin; Hyun-Kyoung Lee; Jin-Young Kim; Chang-Hun Huh; Sang-Woong Youn; Kyoung Chan Park
Journal:  Oxid Med Cell Longev       Date:  2010 May-Jun       Impact factor: 6.543

10.  Understanding mechanisms of vitiligo development in Smyth line of chickens by transcriptomic microarray analysis of evolving autoimmune lesions.

Authors:  Fengying Shi; Byung-Whi Kong; Joon Jin Song; Jeong Yoon Lee; Robert L Dienglewicz; Gisela F Erf
Journal:  BMC Immunol       Date:  2012-04-13       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.